← Human Trials & Peer-Reviewed Studies
Relation of plasma neuropeptide-Y with myocardial function and infarct severity in acute ST-elevation myocardial infarction
Plain-language guide to PMID 38555253 (2024): observational study of Neuropeptide Y in 260 patients.
Key Facts
- PMID
- 38555253
- Journal
- European journal of internal medicine
- Year
- 2024
- Study type
- Observational Study
- Authors
- Tiller C et al. (12 authors)
- DOI
- 10.1016/j.ejim.2024.03.027
What This Study Did, in Plain Language
What Was Tested
This observational study looks at Neuropeptide Y.
This study comprehensively evaluated the association of plasma NPY with myocardial function and infarct severity, visualized by cardiac magnetic resonance (CMR) imaging, in STEMI patients revascularized by primary percutaneous coronary intervention (PCI).
Who Took Part
The abstract describes 260 patients taking part.
PubMed indexes the participants as middle-aged adults and older adults, both men and women.
In this observational study, the researchers included 260 STEMI patients enrolled in the prospective MARINA-STEMI (NCT04113356) study.
How the Study Was Run
Plasma NPY concentrations were measured by an immunoassay 24h after PCI from peripheral venous blood samples.
Left ventricular ejection fraction (LVEF), global longitudinal strain (GLS), infarct size (IS) and microvascular obstruction (MVO) were determined using CMR imaging.
What Was Measured
This study comprehensively evaluated the association of plasma NPY with myocardial function and infarct severity, visualized by cardiac magnetic resonance (CMR) imaging, in STEMI patients revascularized by primary percutaneous coronary intervention (PCI).
The subject headings attached to it are ST Elevation Myocardial Infarction, Neuropeptide Y, Percutaneous Coronary Intervention, Ventricular Function, Left, Stroke Volume, Magnetic Resonance Imaging and Linear Models.
The authors tagged it with the keywords Cardiac magnetic resonance imaging, Myocardial injury, Plasma neuropeptide-Y, Risk stratification and ST-segment elevation myocardial infarction.
What This Means in Plain Language
This is an observational study of Neuropeptide Y in 260 patients.
The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2024 (European journal of internal medicine), a journal based in Netherlands.
More context: the Neuropeptide Y compound page, all human trials.
Our Notes on the Compound
Neuropeptide Y: A 36-amino-acid brain and nerve peptide involved in appetite, stress and blood-vessel tone; studied as an intranasal spray.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.